Fate Therapeutics, founded by stem cell experts, targets $69M IPO – FierceBiotech
|
Fate Therapeutics, founded by stem cell experts, targets $69M IPO
FierceBiotech Fate launched in 2007 with a lot of fanfare in biotech circles, in part because of its plans to harness the power of adult stem cells to treat diseases rather than tapping controversial embryonic stem cells for therapeutic purposes. And a bevy of stem … Stem cell biology company Fate Therapeutics files for $69 million IPOGeekWire Fate Therapeutics Joins Biotech IPO Conga Line, Reaching for …read more    |
